ストックスクリーナーアプリを入手
16.12
5.18%
-0.88
アフターアワーズ：
16.58
0.46
+2.85%
前日終値:
$17.00
開ける：
$17
24時間の取引高:
76,850
Relative Volume:
0.55
時価総額：
$346.69M
収益：
$26.00M
当期純損益:
$-219.71M
株価収益率:
-
EPS:
-
ネットキャッシュフロー:
$-51.37M
1週間 パフォーマンス:
+8.41%
1か月 パフォーマンス:
+15.47%
6か月 パフォーマンス:
-17.33%
1年 パフォーマンス:
+0.00%
1日の値動き範囲:
$15.55
$17.06
1週間の範囲:
$14.00
$17.50
52週間の値動き範囲:
$11.66
$42.60
Cartesian Therapeutics Inc Stock (RNAC) Company Profile
名前
Cartesian Therapeutics Inc
セクター
電話
617-923-1400
住所
704 QUINCE ORCHARD RD, GAITHERSBURG
Cartesian Therapeutics Inc (RNAC) 最新ニュース
1,725 Shares in Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Acquired by Point72 DIFC Ltd - Defense World
Rhumbline Advisers Sells 121,396 Shares of Cartesian Therapeutics, Inc. (NASDAQ:RNAC) - Defense World
Mizuho affirms Outperform on Cartesian Therapeutics stock, highlights Descartes-08’s competitive edge - Investing.com Canada
Logos Global Management LP Invests $2.43 Million in Cartesian Therapeutics, Inc. (NASDAQ:RNAC) - Defense World
Cartesian Therapeutics gets shareholder nod for stock issuance By Investing.com - Investing.com Australia
Logos Global Management LP Buys Shares of 90,000 Cartesian Therapeutics, Inc. (NASDAQ:RNAC) - MarketBeat
Bank of New York Mellon Corp Has $538,000 Holdings in Cartesian Therapeutics, Inc. (NASDAQ:RNAC) - Defense World
Cartesian Therapeutics gets shareholder nod for stock issuance By Investing.com - Investing.com Canada
Cartesian Therapeutics gets shareholder nod for stock issuance - Investing.com
Cartesian Therapeutics gets shareholder nod for stock issuance By Investing.com - Investing.com UK
Cartesian Therapeutics Seems A 'Strong Buy' After Positive Phase 2 Results (NASDAQ:RNAC) - Seeking Alpha
HC Wainwright Reiterates Buy Rating for Cartesian Therapeutics (NASDAQ:RNAC) - Defense World
Cartesian Therapeutics' (RNAC) Buy Rating Reiterated at HC Wainwright - MarketBeat
Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Given Average Recommendation of “Moderate Buy” by Analysts - Defense World
Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Cartesian Therapeutics Receives FDA Rare Pediatric Disease - GlobeNewswire
FDA grants rare pediatric status for Cartesian’s Descartes-08 - The Pharma Letter
Cartesian Therapeutics Gets FDA Rare Pediatric Disease Designation for Dermatomyositis Treatment - MarketWatch
Cartesian Therapeutics Receives FDA Rare Pediatric Disease Designation for Descartes-08 for the Treatment of Juvenile Dermatomyositis - Yahoo Finance
Cartesian Therapeutics Doses First Patient With mRNA CAR-T Descartes-15 in Trial for R/R Multiple Myeloma - CGTLive™
Cartesian Therapeutics Announces New Employment Inducement Grant - GlobeNewswire
Cartesian Therapeutics Announces New Employment Inducement Grant - StockTitan
Cartesian Therapeutics (NASDAQ:RNAC) Receives Buy Rating from HC Wainwright - Defense World
HC Wainwright Reaffirms Buy Rating for Cartesian Therapeutics (NASDAQ:RNAC) - MarketBeat
Cartesian Therapeutics shares maintain Buy rating as new trial kicks off - Investing.com Canada
Cartesian advances new mRNA therapy into Phase 1 trial - Investing.com India
Cartesian advances new mRNA therapy into Phase 1 trial By Investing.com - Investing.com Canada
Cartesian advances new mRNA therapy into Phase 1 trial By Investing.com - Investing.com Australia
Cartesian advances new mRNA therapy into Phase 1 trial - Investing.com
Cartesian advances new mRNA therapy into Phase 1 trial By Investing.com - Investing.com UK
Cartesian Therapeutics Announces First Patient Dosed in First-In-Human Phase 1 Trial of Next-Generation mRNA CAR-T Cell Therapy Descartes-15 - GlobeNewswire
Cartesian Therapeutics Announces First Patient Dosed in First-In-Human Phase 1 Trial of Next-Generation mRNA CAR-T Cell Therapy Descartes-15 - StockTitan
Cartesian Therapeutics Announces First Patient Dosed in First-In-Human Phase 1 Trial of Next-Generation mRNA CAR-T Cell Therapy Descartes-15 - Yahoo Finance
Around the Helix: Cell and Gene Therapy Company Updates – August 28, 2024 - CGTLive™
By 2034, CAR-T Cell Therapy Market Set to Soar USD 8.7 Billion, at 1.80% CAGR: Prophecy Market Insights - GlobeNewswire Inc.
JW Therapeutics’ Relma-Cell Approved in China for R/R Mantle Cell Lymphoma - CGTLive™
Cartesian Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewswire
Cartesian Therapeutics to Participate in Upcoming Investor Conferences - StockTitan
New Spinoza on CAR Ts: Cartesian, others pursue autoimmune - BioWorld Online
RNAC’s latest rating updates from top analysts. - Knox Daily
Hall Laurie J Trustee Has $48,000 Position in Cartesian Therapeutics, Inc. (NASDAQ:RNAC) - MarketBeat
6,315,113 Shares in Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Purchased by Vanguard Group Inc. - MarketBeat
Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Given Average Recommendation of “Moderate Buy” by Brokerages - Defense World
Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Timothy A. Springer Buys 8,016 Shares of Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Stock - Defense World
Thinking about buying stock in Altimmune, UiPath, Incannex Healt - GuruFocus.com
Cartesian therapeutics director Barabe buys $95,250 in stock By Investing.com - Investing.com Australia
Timothy Springer buys $101,967 in Cartesian Therapeutics stock - Investing.com India
Cartesian therapeutics director Barabe buys $95,250 in stock - Investing.com India
Cartesian therapeutics director Barabe buys $95,250 in stock - Investing.com
Cartesian therapeutics director Barabe buys $95,250 in stock By Investing.com - Investing.com Canada
Cartesian Therapeutics Inc (RNAC) 財務データ
収益
当期純利益
現金流量
EPS
0.05%
4.86%
大文字化:
|
ボリューム (24 時間):